New mobile sampling unit takes research into the early detection of lung cancer out into the community
A ground-breaking research trial that aims to save lives by improving the early diagnosis of lung cancer is reaching more people thanks to a new mobile sample collection unit.
The iDx Lung trial is a collaboration between the Cancer Research UK Southampton Clinical Trials Unit at the University of Southampton, the University of Leeds and healthcare and diagnostic companies, and is piloting new diagnostic tests that aim to find ways to detect lung cancer at an early stage when it is more treatable.
People attending the NHS Targeted Lung Health Checks in Southampton, Portsmouth, Manchester and Yorkshire are being invited to take part in the trial, which will offer new types of tests to 7,000 people over the next 3 years.
Since the trial opened to recruitment in June, it has been taking place at the Royal South Hampshire Hospital where the NHS Targeted Lung Health Check vans have been parked. But now, the addition of a new mobile research sample collection unit means the trial team can move around the county reaching more people out in the community.
Professor Gareth Griffiths, Director of the Cancer Research UK Southampton Clinical Trials Unit, said:
“It’s absolutely fantastic because the NHS Targeted Lung Health Check has a large lorry with a CT scanner in the back of it, and when participants come in to have their scan, we are nowable to see those participants in our van. We collect samples and do nasal swabs to try, in the laboratories, to work out if we can detect lung cancer a lot earlier.
“That’s what we have to do with our Cancer Research UK-funded research. We need to go out to the community and try and detect cancer earlier because that's the way in which we are going to be able to beat cancer.”
The trial team are working alongside NHS England’s Targeted Lung Health Checks programme where people at high risk of lung cancer are invited to attend a CT scan in the mobile NHS scanning unit.
Michelle Male, Research Sister in cancer care at University Hospital Southampton NHS Foundation Trust and lead nurse on the iDx Lung trial, said:
“The van gives us the flexibility that we can follow the CT scanner. We’ve got two rooms now as opposed to one before, so we can hopefully recruit more patients. It’s a wider spread community that we can now go to and pick up more patients to take part in the iDx lung trial.”
Left: iDx Lung programme manager Jocelyn Walters and trial manager Darran Ball take delivery of the unit. Right: The iDx Lung team with the new mobile unit (from left to right): Senior clinical trials assistants Irene Woodford, Sarah Bowmer and Lillie Biddlecombe; Director of the SCTU Professor Gareth Griffiths; senior clinical trials assistant Nikki Carney, Research Sister Michelle Male; iDx Lung programme manager Jocelyn Walters.
The iDx Lung trial will ask 7,000 people who attend scans across Hampshire, Yorkshire and Manchester to also give a nasal swab and a blood sample. These samples will be analysed for changes that could indicate the early signs of cancer developing. The aim is to determine whether using simple biological tests alongside the Targeted Lung Health Check programme can help increase diagnosis rates in people with the very early signs of lung cancer, so they can begin treatment quickly when it is far more likely to be successful.
Every year in the UK, 25,000 people are diagnosed with advanced, inoperable lung cancer, making it the biggest cause of cancer death in the UK and worldwide. Screening with CT scanning is being tested by the NHS and it is hoped the iDx Lung trial will not only drive-up early detection rates but will find more cost-effective ways to diagnose the disease.
Professor Peter Johnson, Director of the CRUK Southampton Centre and Chief Investigator of the iDx Lung trial, said:
“We know that lung cancer can be treated successfully if we catch it early, but too often it can go unnoticed and is then picked up at a late stage when treatment options are limited. By bringing some of the latest molecular technology to this problem, we hope that we can find better ways to detect lung cancer in its early stages and make sure people have the best chance of a cure.”
The trial is being funded by a £2.75m grant from UK Research and Innovation’s Industrial Strategy Challenge Fund (ISCF) and £750,000 from Cancer Research UK and is part of a total investment of £10 million from the Government’s Early Diagnosis Mission.
The research collaborators for the trial include Roche Diagnostics, Oncimmune, Inivata, BC Platforms, the Lung Cancer Initiative at Johnson & Johnson, and the Southampton Experimental Cancer Medicine Centre (ECMC) who will carry out the laboratory analysis of the samples.
The iDx Lung mobile research sample collection unit alongside the NHS Targeted Lung Health Checks mobile scanner at Chamberlayne Leisure Centre.
Watch Professor Gareth Griffiths and Michelle Male talk about the arrival of the new unit
Notes for editors
For more information on the NHS Targeted Lung Health Checks , visit https://www.cancerresearchuk.org/about-cancer/lung-cancer/getting-diagnosed/lung-health-checks
Southampton Clinical Trials Unit (CTU) is a Cancer Research UK core funded CTU support funded Clinical Trials Unit with expertise in coordinating well designed studies in cancer, early diagnosis and numerous others area. Based within the University of Southampton with offices at the University Hospital Southampton NHS Foundation Trust Southampton General Hospital site, Southampton CTU will work closely with the NHS England Health Lung Checks programme and industry and other partners to deliver the study. For more information, please visit www.southampton.ac.uk/ctu/index.page
The University of Southampton drives original thinking, turns knowledge into action and impact, and creates solutions to the world’s challenges. We are among the top 90 institutions globally (QS World University Rankings 2021) and top 15 in the UK (The Times and The Sunday Times Good University Guide 2021). Our academics are leaders in their fields, inspiring a 22,000-strong community of exceptional students, from over 135 countries worldwide. As a founding member of the Russell Group, we are committed to using our knowledge to help shape economic, cultural and intellectual decisions, playing a part in researching solutions to national and global issues. The University works in partnership with other universities, businesses and charities to combine resources, in projects such as the £25m state-of-the-art Centre for Cancer Immunology. www.southampton.ac.uk .
Cancer Research UK:
- Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
- Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org .
Southampton Experimental Cancer Medicine Centre (ECMC) is part if the UK ECMC network where world-leading scientists and clinicians drive the discovery, development and testing of new treatments to combat cancer. Southampton ECMC is internationally recognised for its expertise in delivery of early phase cancer studies and strong translational endpoint laboratory with a robust quality management system. For more information, visit https://www.ecmcnetwork.org.uk/southampton